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Comprehensive treatment of locally malignant
tumors using radiomodifications
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In recent years the search for ways to improve the treatment
of malignant tumors is one of the main problems of today.
The problem of treating cancer is particularly relevant for lo-
cally advanced tumors, in which the possibility of surgery is
limited criterion for resectability and operability, and radiati- 
on and medication – a moderate radio- and chemosensitivity
these tumors, particularly when widespread, large-obemu
neoplasms. In the problem of finding more effective treat-
ment of locally advanced tumors of the focus is on develo-
ping methods combined and complex therapy. In developing
methods of pre-exposure are important searches of factors
determining the maximum damage of the tumor, preopera-
tive treatment tolerability, and optimal conditions for post-
operative course. In this direction, a very effective is the use
of various chemical and physical radiomodifiers selectively
modifying the radiosensitivity of tumor cells. When treating
widespread malignant tumors rectum and colon, breast, and
alternative agent for other locations (only 158 pationts)
preoperative combined treatment was carried out using dif-
ferents radiomodifications – sinchronization cell cycle Xe-
loda and 5-FU (monoradiomodification) and in combination
with short-term artificial hyperglycemia (polyradiomodifi-
cation). Assessment of results of preoperative combined treat-
ment with different radiomodifiers testifies to the effective-
ness of the treatment: when using the effect monoradiomo-
dification resorption and tumor regression by 50 % or more
was found in 61 patients (59.8 %), small – less than 50 % – an 
effect was observed in 37 patients (36.3 %) and no effect – in
4 (3.9 %) patients. When using the effect polyradiomodi-
fication resorption and tumor regression by 50 % or more
identified in 37 patients (75.5 %), small (less than 50 %) ef-
fect was observed in 10 patients (20.4 %) and no effect – in 2
(4.1 %) patients. We have developed a comprehensive ap-
proach to treatment with preoperative irradiation effects in
the synchronization of cell cycle Xeloda and short-term arti-
ficial hyperglycemia, not yielding to the effectiveness of
other well-known methods with radiomodifiers, compares
favorably with simplicity in clinical use, requires no special
skills of medical personnel and special equipment and equip- 
ment, which is very important in economic terms.
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The PARP-9/BAL1 encoding gene was reported to be over-
expressed in some high-risk B cell lymphomas [1]. It is regu-
lated by an IFNg-responding bidirectionnal promoter [2]. By 
in situ hybridization in mouse adult organs and during mouse
development, we have revealed that the PARP-9 gene is deve-
lopmentally and differentially expressed in lymphoid organs,
brain and intestine [3]. The PARP-9 protein contains two
macro domains, a domain present in the histone variant mac-
roH2A and described as an ADP-ribose binding module [4].
PARP-9 macro domains were shown to efficiently bind po-
ly(ADP-ribose) [4], supporting the idea that PARP-9 could be
recruited to sites of intense poly(ADP- ribose) synthesis such
as DNA strand breaks. Using live-cell imaging, we have exa-
mined whether GFP-tagged human PARP-9 could be recru-
ited to DNA damaged sites locally introduced by laser mic-
roirradiation. Our results showed that PARP-9 is recruited via
its two macrodomains to DNA damaged sites, in a PARP-1
and poly(ADP-ribose)-dependent manner. To gain insights in- 
to the function of PARP-9 in the DNA damage response, we
have generated animal and cel lular models deficient in PARP-  
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9, by genetic ablation of the Parp-9 gene in mouse and by
shRNA-mediated silencing of PARP-9 expression in human
tumour cells. We have examined the consequence of PARP-9
deficiency on the cellular response to DNA damages introdu-
ced by alkylating agents and ionizing radiations. Results will
be presented, describing PARP-9 as a newcomer in the cell
response to DNA damage. Supported by Centre National de la 
Recherche Scientifique, Universite de Strasbourg and Ligue
Nationale contre le Cancer (Equipe Labellisee).
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Considerable progress was achieved in diagnostics and treat- 
ment of malignant tumors at children during the past decade.
The use of contemporary medical technologies, in particular
radiotherapeutic, also elaboration of the new methods of me-
dicinal antineoplastic therapy makes it possible to cure up to
70–80 % of the sick children. As well as in other countries,
pediatric oncology in Armenia is one of the youngest bran-
ches of clinical oncology. The first and unique Pediatric On-
cology Department (POD) with 20 beds was opened on the
base of National Centre of Oncology in 1994. Diagnostics
and treatment of all kinds of benign and malignant tumors
except for leukemia is carried out in POD. The mostly occu-
rring pathologies are: non-Hodgkin’s and Hodgkin’s lym-
phomas (15–18 %), bone sarcomas and PNET (10–12 %),
Wilms’ tumor (7–8 %), germ cell tumors (7 %), neuroblas-
toma (5–6 %). Among the benign tumors hemangiomas are
uppermost and criotherapy is widely applied at their treat-
ment. Medicinal therapy is the basic method in complex treat-
ment of malignant neoplasms. The chemotherapy of tumours 
at children has frequently intensive character that demands
applying multicomponent supportive care – one of the scien-
tific directions of POD. Thus the frequency of such com-
plications of chemotherapy as thrombocytopenia and leuco-
penia has considerably decreased. Limb salvage operations,
specifically endoprosthesis replacement are widely applied
in surgery. The weak point in pediatric oncology service in
our country is absence of the unit of stem cells and bone mar-
row transplantation which necessity appears at resistant and
relapsing tumors. It should be mentioned that there are cases
of treatment of malignant solid and system tumors of child-
hood in non-oncological hospitals that leads to tactical mista-
kes. Leukemia is traditionally and rather successfully treated
at pediatric department of Hematology Center. Analyzing
and comparing the achievements of pediatric oncology in de- 
veloped countries during the past 10 years we consider that
there are a number of serious problems hindering the further
progress in treatment of childhood cancer in Armenia. First it 
is necessary to resume teaching of the subject «children’s
oncology» to the students of Yerevan State Medical Univer-
sity on the base of National Centre of Oncology and to raise
prestige of the profession. We consider essential and vital
mobilization of all available resources and building of the Re-
publican Center of Pediatric Oncology and Hematology.
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Earlier we have demonstrated that hemorphins in vitro modu-
late Ca2+/calmodulin (CaM)-dependent protein phosphata-
se calcineurin activity by binding to CaM, exhibiting a concen-
tration-dependent biphasic response on enzyme activity. It is
well known that calcineurin controls gene expression of seve-
ral cytokines, including IL-2, tumor necrosis factor a and
others via dephosphorylation and nuclear translocation of 
NFATc (nuclear factor of activated T cell) family members.
Calcineurin/NFAT pathway is involved in pathophysiolo-
gy of cancer as well (Padma S. et al., Cancer Cell Int., 2005).
The immunosuppressive drugs cyclosporin A (CsA) and
FK506 are inhibitors of calcineurin. Both these compounds
exert their inhibitory action on calcineurin activity by bin-
ding to immunophilins (cyclophilin A and FKBP12, res-
pectively) (Liu J. et al., Cell, 1991). It has been found out that 
in vivo inhibition of calcineurin activity by CsA and FK506
induces apoptosis of leukemic cells and rapid tumor clearan-
ce in lymphoblastic leukemia (Medyouf H. et al., Nature Me- 
dicine, 2007). The goal of present study was to determine if
hemorphins may affect tumor growth and regulate plasma
and brain calcineurin activity in vivo in rats bearing sarco-
ma-45 (S-45). In the experiments were used 3 synthetic he-
morphins: LVV-hemorphin-7, hemorphin-7 (H-7) and
LVVYPW. Results obtained demonstrated that intraperito-
neal (ip) administration of rats bearing S-45 with synthetic
hemorphin (1 mg/kg) recovered plasma and brain calcineu-
rin activity reduced in pathophysiology of S-45. It is propo-
sed that hemorphins act as homeostatic agent. Moreover, 8
days treatment of rats bearing S-45 with hemorphins (single
ip injection of hemorphin daily) resulted in the inhibition of
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tumor growth. The most pronounced inhibition of tumor
growth was induced by ip injection of H-7 (by 44.9 %). Re-
cently, by using proteomics approaches in collaboration with 
Dr. F. Lottspeich (Department of Protein Analysis of Max-
Planck Institute of Biochemistry, Martinsried, Germany),
peptidyl-prolyl cis-trans-isomerase A (cyclophilin A) was
identified as regulated (1.8 fold down regulation) by hemo-
rphins protein in healthy mouse brain (Barkhudaryan N. et
al., Neurochem. Res., 2010). It should be noted that by using
cDNA microarray, among genes up-regulated in the colon
cancer was peptidyl-prolyl isomerase-like 1 encoding PPIL1,
a cyclophilin-related protein. It was suggested that develop-
ment of drugs to antagonize the function of PPIL1 may be a
good strategy for therapy of colon cancer (Obama K. et al.,
Clin Cancer Res., 2006). Importantly, it has been shown that
H-7 regulates DNA-binding activity of NF-AT, AP-1 and
NF-kB transcription factors in stimulated Jurkat T cells (Bar- 
khudaryan N. et al., Blood (RA), 2010). It is very likely that
the ability of hemorphins to regulate transcriptional activity
and change the expression level of some proteins involved in
pathophysiology of cancer (e. g. regulation of the expression
of cyclophilin A) may explain their anticancer effect.
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A growing amount of data has indicated the involvement of
autoimmune reactions in etiology and pathogenesis of many
neuropsychiatric disorders. However, for a majority of the
diseased conditions the molecular pathomechanisms respon- 
sible for the development of autoimmune reactions and their
relationships with other molecular and cellular level changes 
associated with the diseased condition remain unclear. The
present report summarizes our recent investigations on the
involvement of autoimmune processes in pathogenesis of
complex polygenic neuropsychiatric diseases including stro- 
ke, schizophrenia and posttraumatic stress disorder [1–7].
Patients with the above mentioned diseased conditions as
well as sex- and age matched healthy volunteers were invol-
ved in the studies. Among autoimmunity markers, different
subpopulations of circulating immune complexes, including
pathogenic immune complexes and cryoglobulins were stu-
died. Special attention was focused on the immune comp-
lexes containing complement cascade initiating C1q protein
and opsonins derived from C3 component protein during the
activation of the complement cascade. Both blood levels and
molecular composition of the immune complexes have been
evaluated, and disease-specific antigens have been revealed
for each diseased condition. In addition, the expression pro-
files of proinflammatory and immunoregulatory cytokines as 
well as blood levels of neuron-specific proteins (neuron-spe- 
cific enolase and S-100b) were assessed. Cytokines profile
includes both interleukins (tumor necrosis factor-a, interleu- 
kine-1-b, interleukine-6) and chemokines (monocyte chemo- 
attractant protein-1, and cytokine induced neutrophil chemo- 
attractant protein). Methodological design was mainly based
on enzyme-linked immunosorbent assays (ELISA), protein
chemistry, immunochemistry, and bioinformatics methods.
The results obtained indicate that all studied diseases are cha-
racterized by the development of autoimmune processes. Cor- 
relation analysis between  the measured parameters and those
indicating pathogenesis of diseased conditions reveals positi-
ve correlation between the intensity of autoimmune reacti-
ons disease progression and severity, on the on hand, and bet-
ween the intensity of autoimmune processes and blood-brain
barrier dysfunction, on the other. The data obtained allow iden- 
tifying two types of autoimmune reactions developed in tar-
geted diseases. One type is developed due to pathologic chan-
ges in structural and functional integrity of blood brain barrier, 
and another, due to increase in the level of acute phase prote-
ins. In both cases a low grade inflammatory response (neuro-
inflammation and low-grade systemic inflammation) and aber- 
rant apoptosis have been identified as triggering factors.
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rol. Psikhiat. Im. S. S. Korsakova.–2005.–105, N 4.–P. 55–60.
Hypothalamic cytokine Galarmin is an inhibitor of
mesenchymal tumors  
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Activation of the PI3K-Akt-mTOR pathway is implicated
both in the establishment of tumors and as well as a target for
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therapy in many types of solid malignancy, its blockade re-
presents an opportunity to improve outcomes in patients with 
tumors that are associated with poor prognosis. The mam-
malian target of rapamycin (mTOR) is an intracellular se-
rine/threonine protein kinase that has a crucial role in a nutri- 
ent sensitive signaling pathway that regulates cell growth.
Our experimental data indicates that proline rich polypep-
tide-1 (PRP-1, Galarmin), immunomodulator cytokine, pro-
duced by hypothalamic neurosecretory cells, exerts its anti-
proliferative effect on the tumor cells of mesenchymal origin
such as chondrosarcoma, giant cell tumor, lymphosarcoma,
and MDA 231 high metastatic breast carcinoma (in an epi-
thelial-mesenchymal transition) via inhibiting mTOR kinase
activity and repressing cell cycle progression. The goal of
these investigations was to elucidate the antiproliferative ac-
tion of PRP-1 on the breast carcinoma cell line MDA 231
(ER–) and to compare PRP-1 action previously reported on
other mesenchymal tumors. These experiments confirmed
maximum inhibition of cell growth at 0.5 and 1 mg/ml PRP-1
(71 % and 63 %, respectively) and inhibition at 10 mg/ml of
44 %. There was no inhibitory effect observed on luminal
T47-D (ER+) cells. Videomicroscopy results demonstrated
dividing cells in the cytokine-treated MDA 231 (ER–), sug-
gesting that the cells were not in the state of dormancy. The
flow cytometry synchronization experiments confirmed that
PRP-1-treated cells were accumulated in S phase. No apopto-
sis, caspase activation, or senescence was detected after treat-
ment with this cytokine. Experiments with mTOR with PRP-
1 (10 mg/ml) indicated statistically significant 40 % inhibi-
tion of mTOR kinase activity in immunoprecipitates of the
MDA 231 (ER–) cell line. PRP-1 is a novel mTOR inhibitor
with strong antiproliferative action in mesenchymal tumors
mostly resistant to radiation and chemotherapy. One can spe- 
culate that PRP-1 chooses the same signaling routes for the
tumors of mesenchymal nature, which presents interesting
challenge for the future exploration on whether or not the
genetic signatures defining the neoplasm also seal the niche
for the metastasis for mesenchymal tumors. More experi-
ments are needed for further understanding of the cytostatic
effect of PRP-1 on cell cycling in vivo on the animal model.
PRP-1 has compelling molecular antitumor properties that
may make it a candidate for new adjuvant therapy trials alone 
or in combination with other chemotherapeutic agents for the 
treatment of mesenchymal tumors.
The incidence and mortality of malignant tumours
in Armenia
H. M. Galstyan, G. K. Bazikyan. P. B. Poghosyan
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The fight against malignant tumours is not only a health sys-
tem issue, it has a state significance due to annual increasing
incidence rate in almost all countries of the world (2–4 % on
average), high levels of health problems and the absence of
decrease in mortality rate. Now, how is the situation in Ar-
menia for last 10 years. In 2000 the incidence rate was 142.3
patients per 100.000 population (5413 primary patients –
new cases), in 2010 it composed 233.0 (7584 patients), the
increase was 90.7 unit. In 2000 amongst  primary patients the 
early (I and II) stages were diagnosed in 56.0 % cases, in
2010 – in 50.0 % of cases. Thus, there was no progress in the
fight against negligence of malignant tumours. The mortality 
from malignant tumours was the following. During last 10
years the rate has increased by 74.1 unit (7.1 unit per year),
while the increase in incidence rate during that period com-
posed 90.7. Therefore the incidence rate has increased faster
than mortality rate. In general structure of malignant tumours 
during last decades lung cancer was in the leading position,
the intensive rate of which during last 5 years has increased
by 3.6 unit, in 2010 it composed 36.7 per 100.000 populati-
on. The second prevalent malignancy was breast cancer, the
intensive rate of which has increased by 3.1 unit, in 2010 it
composed 58.5. By frequency next tumours are stomach,
colon, cervical, prostate cancers, leucaemias and lympho-
mas, bladder, endometrial, ovary, rectal, laryngeal carcino-
mas. Exploring the incidence rate of separate tumous in Ar-
menia by mapping we determined a quite mosaic picture.
The highest level of incidence was estimated in Lori region:
290.7 per 100.000 population, then in Kotayk and Shirak re-
gions – 254.0, in Yerevan – 241.2. In the rest regions inci-
dence ranged between 200.0 and 221.0 limits. The lowest in-
cidence rate was established in Gegharquniq region – 166.8.
Carcinoma in situ of the breast: riddles and
controversies
H. M. Galstyan,  M. D. Kostanyan 
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Carcinoma in situ is the earliest histologically recognizable
form of malignancy and such provides an opportunity to treat 
the disease in a curative way. Because of widespread scree-
ning for breast cancer, noninvasive (in situ) cancer of the
breast is diagnosed with increased frequency. There are 2 ty-
pes of breast cancer in situ – lobular cancer in situ (LCIS)
and ductal cancer in situ (DCIS). Both LCIS and DCIS are
forerunners of invasive breast cancer but with different beha- 
viour. The management of in situ cancer (especially, DCIS –
intraductal carcinoma) is one of the most  complex and con-
troversial topics in the treatment of breast cancer. There are
widely disparate philosophies  concerning  diagnosis, classifi-
cation and  treatment. LCIS is a marker for increased risk of
invasive cancer in both breast (in homolateral breast in 18 %
and in heterolateral breast in 14 % of cases after 20 years), it
is likely to be bilateral. Treatment options of LCIS include
observation (after surgical excision) without sentinel lymph
node biopsy (SLNB) or axillary lymph node dissection. So-
me patients with high risks of breast cancer should be po-
tential candidates for bilateral mastectomies. DCIS is defined
as a carcinoma of ductal epithelial origin, without any evi-
dence of stromal invasion. Laboratory and patient data sug-
gest that DCIS is a precursor lesion for invasive cancer. The
appropriate classification of DCIS has provoked much deba-
te; a number of classification systems (Van Nuys, AFIP clas-
sification systems) have been developed, but there is a lack
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of uniformity in the diagnsosis and prognostification of this
disease. Further investigation of molecular markers should
improve the classification of DCIS and our understanding of
its relationship to invasive disease. Controversy also exists
with regard to the optimal management of DCIS patients. In
the past, mastectomy was the primary treatment for patients
with DCIS, but as with invasive cancer, breast-conserving
surgery has become the standard approach. The incidence of
axillary lymph node metastases in DCIS is negligible (up to 4 
%, 3.5 % – in our study). According to ASCO recommen-
dations, SLNB is acceptable when a mastectomy is indicated
or when immediate breast reconstruction is  planned. In pa-
tients who undergo breast conserving therapy, SLNB is re-
commended in cases of large or high-grade DCIS. Three
randomized trials have reported a  statistically significant
decrease in the risk of recurrence with radiation therapy in
combination with lumpectomy alone, but there was no survi-
val advantage with the addition of radiotherapy. Two rando-
mized trials have suggested an additional benefit, in terms of
recurrence, with the addition of adjuvant tamoxifen therapy,
although in one trial the benefit was not statistically signi fi-
cant. Current data suggest that tamoxifen use should be res-
tricted to patients with estrogen-positive DCIS (ER-positive
in 70 % – lower in high grade; HER2/neu positive in 50 % –
higher in high grade). Neither trial demonstrated a survival
benefit with adjuvant tamoxifen. 
Co-temporal replication and transcription in long
genes induces common fragile site breakage that
can be prevented by inhibiting R-loop formation
A. Helmrich, L. Tora
Institute of Genetics and Molecular and Cellular Biology, 
Strasbourg, France
laszlo@igbmc.u-strasbg.fr
Background. Almost all eukaryotic genes are transcriptio-
nally silent during the S-phase of the cell cycle to prevent col-
lisions between the RNA polymerase II transcription appa-
ratus and the replication machinery. When transcription and
replication machineries encounter in bacteria or yeast, repli-
cation forks have been shown to stall and genomic recombi-
nation rates increase. It was also demonstrated that cotrans-
criptionally arising RNA:DNA hybrids (R-loops) contribute
to genome instability. Human cells contain specific genomic
regions, which are prone to breakage and rearrangement for-
mation. These chromosomal regions are called common fra-
gile sites (CFS) and can be detected in metaphase spreads as
gaps and breaks in the chromatin. However, the mechanism
of CFS formation remains largely unknown. Aim. We asked
whether the transcription of genes would par ticipate in CFS
formation. We show that (i) CFSs are often found in very long
coding regions and that (ii) the breakage of CFSs depend on
the active transcription of these very long genes underlying the
CFS regions. By analyzing the transcription timing of these
CFS-associated human genes, we found that the corres-
ponding extremely long transcripts are produced over more
than one cell cycle, consequently also in S-phase. Moreover,
our experiments demonstrate that the genomic regions coding
for these long CFS-associated genes replicate in late S-phase,
independently whether they are transcribed or not. Thus, CFS
breakages appear in very long genes (about 1 Mb or more) that 
are transcribed and replicated about the same time in late S-
phase. Furthermore, we were able to reduce the breakage of
chromosomes in the CFS regions when we eliminated the co-
transcriptionally arising R-loops by overexpression of RNase
H1 that is known to hydrolyse R-loops. Conclusions. Thus,
our results reveal that CFS instability is based on the forma-
tion of R-loops on very long genes, but only when replication 
and transcription occur at the same time.
Oxidative modifications of biomolecules upon
neurodegenerative processes
L. M. Hovsepyan, G. S. Kazaryan, A. A. Hakopjanyan 
Institute of Molecular Biology, NAS of Republic of Armenia, Yerevan
l_hovsepyan@mb.sci.am
The Parkinson’s disease (PD) is a neurodegenerative disor-
der accompanied by movement-related, neuropsychiatric
and vegetative problems. Progressive disease development,
inadequate therapy, heavy disablement of the majority of pa-
tients turn the PD into a serious social issue. The objective of
the present work was the study of the oxidative destruction
of proteins and lipids in mitochondrial fraction of the brain in 
animals with experimentally induced syndrome of PD. The
experimental PD syndrome was induced in rats by 1-methyl-
4-phenyl-1,2,3,6-tetrapyridine. It was shown that the deve-
lopment of PD leaded to increase of hydroperpxides and
malone dialdehyde in mitochondrial fraction of the brain.
Analysis of oxidative damage of proteins at induced PD
shown the statistically reliable increase of protein carbonyl
derivatives. The rate of oxidative protein modification is
known to be determined by the amino acid composition of
proteins. The levels of aliphatic aldehyde and ketone dinitro- 
phenyl hydrasones increased, that suggested the acceleration 
of oxidative destruction of proteins.  It was concluded that
the oxidative modification of lipids and proteins occurs at
PD and, probably, plays an essential role in pathogenesis and 
development of this disease.
Oncogenic and anti-oncogenic properties of genes
with significantly changed expression in brain tumors
V. M. Kavsan, P. A. Areshkov, V. P. Baklaushev1,
 O. V. Balynska, S. S. Avdieiev, V. P. Chekhonin1,
 A. A. Mekler2, Yu. A. Zozulya3 
Institute of Molecular Biology and Genetics, NAS of Ukraine, Kyiv 
1V. P. Serbsky National Research Centre for Social and Forensic
Psychiatry, Russian Ministry of Health, Moscow, Russian Federation
2Institute of Human Brain, RAS, St. Petersburg, Russian Federation
3A. P. Romodanov Institute of Neurosurgery, Kyiv, Ukraine 
kavsan@imbg.org.ua
An important task in understanding oncogenesis is the identi-
fication of those genes whose copy number and expression
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increase during tumorigenesis. In an effort to identify mo-
lecular markers for glial tumors, we compared gene ex-
pression in glioblastoma, the most aggressive form of brain
tumors to the normal brain cells. Among the genes with the
most pronounced increased expression in tumors was
CHI3L1, encoding the secreted chitinase 3-like 1 protein.
CHI3L1 can decrease the doubling time of 293 cells, allows
the anchorage independent growth in soft agar and in
addition, stable CHI3L1 expression made 293 cells tu-
morigenic: these cells stimulated the initiation of tumors
after their transplantation into the rat brains. The ac-
tivation/inactivation kinetics of the signaling pathways has
been associated with specific outcomes. 293_CHI3L1 cells
activated extracellular signal-regulated kinases (ERK1/2)
MAPK and AKT-mediated phosphoinositide 3-kinase
(PI3K) pathways; phosphorylated ERK1 and ERK2 were
localized in both cell cytoplasm and nuclei while AKT only
in cytoplasm. 293_CHI3L1 cells differed from 293 cells
transfected by an «empty» vector in their size and ability to
adhere to the culture plate. Chitinase 3-like 2 (CHI3L2) most 
closely related to human CHI3L1 also showed increased ex-
pression in glial tumors at both the RNA and protein levels
and stimulated the activation of the MAPK pathway through
phosphorylation of ERK1/2 in 293 and U373 cells. In
contrast to the activation of ERK1/2 phosphorylation by
CHI3L1 that lead to a proliferate signal (similar to the EGF
effect in PC12 cells), activation of ERK1/2 phospho-
rylation by CHI3L2 (similar to NGF) inhibited cell mito-
genesis and proliferation, thus possessed anti-oncogene pro-
perties. In addition we found one more antagonist to onco-
gene CHI3L1, the tumor suppressor gene TSC22 with de-
creased expression on mRNA and protein levels in glial
brain tumors. TSC22 inhibited cell proliferation and may
serve as a mediator of apoptosis stimulated signal from TGF-
b1. Thus, the overexpression of CHI3L1 is likely to have an
important role in tumorigenesis and orthotopic implantation
of transformed human cells with overexpressed human
oncogene CHI3L1 to the rat brain presents a new model of
human brain tumor which can be used as a target for an-
ticancer drug development. Address influence on oncogenes
is becoming a clinical reality, however the therapy aimed
against one singular gene will be not really effective because
of huge bio logical heterogeneity of tumors. At present it is
understandable that the establishment of specific signature
of gene expression for every tumor type is obligatory for
their more effective therapy. Two years ago we elaborated
sample of «gene expression prediction», namely a 10-genes
glioblastoma signature. More precise signature was obtained 
by so called self-organized Kohonen’s map (SOM) using in
this case twenty genes significantly changed their expression 
in about two hundred glioblastoma and seventy normal brain
samples. Obtained data clearly show the clusterization of
glioblastoma and normal brain samples. Moreover, self-
organized Kohonen’s mapping of the data obtained with sa-
me twenty genes significantly changed expression in more
than 400 samples of different grade astrocytomas and
normal brain allowed to separate clusters of samples from
patients with pilocytic astrocytoma, diffuse astrocytoma,
anaplastic astrocytoma, glioblastoma, and samples of nor-
mal brain.  
High frequency stimulation of the subthalamic
nucleus impacts adult neurogenesis in a rat model of 
Parkinson’s disease
L. Kerkerian-Le Goff1, V. Khaindrava1, 2, C. Melon1,
 P. Salin1, M. Ugrumov2, A. Daszuta1
1IBDML, UMR 6216 CNRS, University of Mediterranee, Marseille,
France
2P. K. Anokhin Institute of Normal Physiology, RAMS, 
Moscow, Russian Federation 
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Aim. Dopamine loss in Parkinson’s disease (PD) affects
adult neurogenesis in the two main neurogenic regions (the
subventricular zone-rostral migratory stream-olfactory bulb
continuum and the dentate gyrus of the hippocampus), with
presumed involvement in non-motor symptoms, such as hy-
posmia and depression. This study addresses the impact of
prolonged subthalamic nucleus high frequency stimulation
(STN-HFS), an efficient therapeutic option for the treatment
of motor symptoms in advanced PD, on adult neurogenesis
in a rat PD model. Knowing that neurogenic changes can be
involved in antidepressant action, we also looked for its
effect on depressive-like behavior. Methods. Unilateral le-
sion of the nigrostriatal dopamine neurons was performed by 
intranigral 6-hydroxydopamine injection. STN-HFS was ap- 
plied continuously during 8 days in freely moving rats
through an implanted electrode on the same brain side with
the following parameters: frequency 130 Hz, pulse width 80 
ms, intensity 80 mA. The forced swim test was used to assess
the antidepressant action of STN-HFS. Two steps of neuro-
genesis were investigated, proliferation (Ki-67-immunopo-
sitive cells) and survival (cells immunopositive to BrdU, a
thymidine analogue that labels dividing cells in situ by
incorporation in the DNA, given by systemic administration
at the first day of HFS), in the two above-mentioned neuro-
genic regions. Results. Dopamine lesion has a negative con-
sequence on both cell proliferation and survival through dif-
ferent mechanisms, the effect on proliferation being correla-
ted to the level of striatal dopamine denervation whereas the
effect on survival is not. In the two neurogenic zones, STN-
HFS does not act on cell proliferation but promotes the sur-
vival of newly formed cells both in the ipsi- and contralateral
sides, suggesting the involvement of a complex neural net-
work in the control of this critical phase of neurogenesis. Re-
garding behavior, in contrast with a previous report showing
that acute STN-HFS impairs performance in the forced swim 
test, we found improved performance in this test following
prolonged STN-HFS. Conclusions. Altogether, these data
suggest that chronic STN-HFS has a positive action on adult
neurogenesis that is not directly linked to dopamine tone and
might have an antidepressant-like potential. They strongly
support the view that this neurosurgical treatment can largely 
impinge brain function and neuroplasticity. We are now
using an implantable microstimulator allowing chronic HFS
in behaving rats to identify the phenotype of newly formed
cells and further investigate the motor and non-motor beha-
vioral outcomes of the long term neurosurgical treatment.
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Iatrogenic aplasia induced by chemotherapy and
treatment with «proline rich peptide»
G. A. Kevorkian, H. L. Hayrapetyan, A. G. Guevorkian, 
K. A. Barsegyan, A. A. Galoyan
H. Buniatian Institute of Biochemistry, NAS of Republic of Armenia, 
Yerevan
ggevorgyan@sci.am
The patients with breast cancer of the 4th degree (according to
the international classification) with metastasis injury of the
bone, and unable to independent movement, as well as with-
out surgical intervention on breast, received a full rate of irra-
diation treatment and chemotherapy by doxorubicin and cyc-
lophosphamide solution. On the 3–4 days after chemotherapy
and definition of quantity of leukocytes, the patient was trea-
ted with subcutaneous (before sleeping) application of Proline 
Rich Peptide (PRP), which is a polypeptide from bovine hypo- 
thalamus, with quantity of a single doze of 70 mcg with an in-
terval in one day within 5 days, i. e. three injections in a total do- 
ze of 210–220 mcg. Study of the spectrum of leukocytes’ con-
dition shows that during the irradiation the following changes
have been registered: The 1st fraction of leukocytes 30–100 fl
(fl = mcm3), representing a picture of fraction lymphocytes in
a population of leukocytes, is not exposed to special changes.
Their quantity changes from 1.0 K/ml at pretreatment up to 1.2
K/ml at post-treatment with PRP. Thus, the quantity of lympho-
cytes reduces up to 30 % after chemotherapy, and rises after
PRP application. Monocytes (medium-sized blood cells), as
well as basophils and eosinophils settle down on the histo-
gram in the field of 100–150 fl and remain on the former level
irradiation, and do not vary after the application of PRP (0.3 K/
ml). Granulocytes or neutrophils, representing the largest blo-
od cells with polysegment nucleus in the populations of leuko- 
cytes, are reduced after chemotherapy up to 0.17 K/ml, and
grow up to 1.9 K/ml after PRP application. After therapy the in- 
dicative condition of granulocytes increases after PRP appli-
cation up to 155–350 K/ml. The quantity of granulocytes under 
influence of PRP grows by 950 %. According to the histogram 
both the quantity and also the volume of granulocytes increa-
se, thus indicating their full physiological value. A cytogene-
tic observation of the lymphocytes culture after chemotherapy 
and 3-fold administration of PRP (by 75 mg) is carried out star- 
ting from the 5th day after finishing the chemotherapy course.
The analyses are made from the 6th day after the final admi-
nistration of PRP. The caryotype 44/XX is defined, the level
of chro- mosome aberrations being 7.4 %. The quantity of tet-
raploid cells (4 p) was 0.55 per 100 cells. The opportunity of
application of a preparation in clinic is discussed.
Modeling of parkinsonism in mice: mechanisms of
neuroplasticity
G. R. Khakimova1, 2 , M. V. Ugrumov1, 2 
1Koltsov Institute of Developmental Biology, RAS, Moscow, Russian
Federation
2P. K. Anokhin Institute of Normal Physiology, RAMS, 
Moscow, Russian Federation
michael.ugrumov@mail.ru 
A degradation of the nigrostriatal dopaminergic (DA-ergic)
system is the key component of pathogenesis of Parkinson’s
disease (PD). Initial clinical symptoms appear 20–30 years
after the onset of neurode-generation, at a 70 % DA deple-
tion in the striatum and a 50 % loss of nigral DA-ergic neu-
rons. Low efficacy of the therapy might be improved if precli-
nical diagnostics and preventive therapy are developed. The
development of appropriate experimental models should pre-
cede clinical trials. This multidisciplinary study first mana-
ged to model in mice with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) all together the following stages
of parkinsonism: (a) the early presymptomatic stage
manifested by a subthreshold degeneration of axons and DA
depletion in the striatum without loss of nigral cell bodies;
(b) the advanced presymptomatic stage manifested by a
subthreshold degeneration of striatal axons and DA
depletion and by a subthreshold loss of nigral cell bodies; (c)
the advanced presymptomatic stage characterized by
threshold depletion of striatal DA and a loss of DA-ergic
axons and nigral cell bodies resulting in motor dysfunction.
The degeneration of axons proceeds and prevails that of cell
bodies suggesting higher sensitivity to MPTP of the former.
Compensatory processes were developed in parallel to
neurodegeneration that was manifested by the increase of: (i) 
the DA content in individual nigral cell bodies and DA
turnover in the striatum, (ii) the tyrosine hydroxylase gene
expression and activity, (iii) DA release, (iv) DA synthesis in 
non-dopaminergic neurons. The above processes appear to
prevent a development of motor disorders at the presymp-
tomatic stage. A transition from the presymptomatic stage to
the symptomatic one appears to be provoked by a decrease of 
DA release and an increase of DA uptake apparently
resulting in a drop of the intercellular concentration of DA.
The developed models might be exploited for: (a) an exami-
nation of pathogenetic mechanisms not only in the nigro-
striatal system but also in other brain regions and in the peri-
phery; (b) a study of the compensatory mechanisms under
DA deficiency; (c) a search of precursors of motor disor-
ders and peripheral biomarkers in presymptomatic parkin-
sonism; (d) the development of preventive therapy aiming to
slow down the neurodegeneration and strengthen compen-
satory processes. Thus, the models of the early and advanced
presymptomatic stages and of the early symptomatic stage of 
parkinsonism were developed in mice with MPTP.
The nucleic acid binding properties of CSD of
human YB-1
V. Kljashtorny, S. Nikonov, L. Ovchinnikov, P. A. Curmi1,
P. Manivet1
Institute for Protein Research, RAS, 
Pushchino, Moscow Region, Russian Federation
1Structure and Activity of Normal and Pathological Biomolecules
Laboratory, INSERM-UEVE U829, Evry, France
mail
The nucleic acid binding properties of CSD of human YB-1
has been investigated with molecular dynamics (MD)
simulation method. It has been shown that CSD can signi-
ficantly determine the specificity of the whole YB-1 protein
to both RNA and DNA. MD simulation revealed a higher
affinity of CSD to RNA sequences as compared with similar
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DNA sequences. This is directly related to the contacts for-
med by OH-groups of ribose residues. A cap-binding site on
the surface of CSD has also been proposed. Although we
have not observed very stable interactions between CSD and
the cap-structure of mRNA, these interactions should increa- 
se the affinity of YB-1 to capped mRNAs. Finally, we perfor-
med simulation of the phosphorylated CSD and its comple-
xes with nucleic acids. Phosphorylation of CSD on Ser102
leads to a slightly decreased affinity of CSD to nucleic acids
especially DNA sequences. The next question to be addres-
sed is how this phosphorylation may influence the interac-
tion of YB-1 with RNA cap-structure.
Apurinic/apyrimidinic (AP) site recognition by poly 
(ADP-ribose) polymerase 1 and other key proteins
of human cells
O. I. Lavrik, S. N. Khodyreva, E. S. Ilina, M. M. Kutuzov,
M. V. Sukhanova, R. Prasad1, S. H. Wilson1, J.-C. Ame2,
V. Schreiber2, V. Joshi3, P. Curmi3, L. Hamon3
Institute of Chemical Biology and Fundamental Medicine, SB RAS,
Russian Federation
1FRE3211, IREBS, CNRS, University of Strasbourg, ESBS, France
2NIEHS, National Institutes of Health, Research Triangle Park, NC
27709, USA
3French National Institute of Health and Medical Research (INSERM), 
UMR829; University Evry-Val d’Essonne, France
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Aim. DNA repair is a central mechanism to keep integrity of
cell genome. Several pathways are involved in repair of
DNA damages arising under the action of endogenous or
exogenous stress among them base excision repair (BER).
One of the most abundant lesions in DNA are the apurinic/
apyrimidinic (AP) sites arising spontaneously or as interme-
diates in BER at a frequency of 10.000 to 50.000 lesions per
mammalian cells per day. AP sites can appear also under the
action of ionizing radiation and can be components of cluster 
lesions in DNA. AP sites are unstable and cytotoxic. AP sites 
within nucleosome produce significant amounts of DNA-
protein cross-links and generate double-strand breaks, the
most deleterious form of DNA damage. Repair of these lesi-
ons is the central task for protecting DNA structure. The aim
of this work was to identify proteins which can interact with
AP sites to regulate repair of these abundant DNA lesions.
Methods. We applied DNA derivatives containing AP sites
as tool to cross-link target proteins in the extracts of mamma- 
lian cells. The target proteins were identified by MALDI-
TOF mass spectrometry after borohydride trapping of Schiff
bases in DNA-protein adducts and purification of DNA-pro-
tein adducts on the affinity column. Interaction of proteins
with AP site-containing DNA was analyzed by biochemical
methods and proved by atomic force microscopy (AFM).
Results. The capacity of human poly(ADP-ribose) polyme-
rase-1 (PARP-1) to interact with intact AP sites in DNA has
been demonstrated. In cell extracts, sodium borohydride re-
duction of the PARP-1/AP site DNA complex resulted in co-
valent cross-linking of PARP-1 to DNA; the identity of
cross-linked PARP-1 was confirmed by mass spectrometry.
Using purified human PARP-1, the specificity of PARP-1
binding to AP site-containing DNA was confirmed in com-
petition binding experiments. PARP-1 was only weakly acti- 
vated to conduct poly(ADP-ribose) synthesis upon binding
to AP site-containing DNA, but was strongly activated for
poly(ADP-ribose) synthesis upon strand incision by AP en-
donuclease 1 (APE1). By virtue of its binding to AP sites,
PARP-1 could be poised for its role in base excision repair,
pending DNA strand incision by APE1 or the 5'-dRP/AP lya- 
se activity in PARP-1. Interaction of PARP-1 with DNA,
containing AP-sites was detected using AFM-imaging of
protein-nucleic acid complexes. Another member of PARP
family – poly(ADP-ribose) polymerase 2 – shows interaction 
with AP site-containing DNA. Further characterization of
PARPs interaction with AP site-containing DNA and its im-
plications will be discussed. It was revealed that other co-
factor proteins of the BER system – XRCC1 and HMGB1 –
are also able to interact with AP sites. Conclusions. There-
fore, it is likely that one of the functions of PARP proteins
consists in regulation of AP site repair. One can expect con-
tribution to this process of other protein factors of DNA re-
pair complex. This work was supported by RFBR grants nos
09-04-93106, 10-04-01083, 11-04-00559, State contract
16.512.11.2241 and Program of RAS on Molecular and Cel-
lular Biology.
Embryonal proteoglycans and counteraction to a
tumour growth
L. Mkrtchyan
Russian-Armenian Medical Centre «D-P», JSC, Yerevan, 
Republic of Armenia
mln-38@mail.ru 
The cancer epidemic has captured the modern society. Accor-
ding to the World Organization of Public Health, 13–15 mil-
lion inhabitants of our planet are affected by cancer every
year. The cancer morbidity increases annually by 3 percents
in Armenia, while 390,000 new cases are registered in the
Russian Federation. Each fourth and now even the third in-
habitant of our planet dies of cancer. The National Cancer In- 
stitute of the USA, which is one of the leaders of the funda-
mental oncology, recommends turning the vector of the anti-
cancerogenic struggle aside the preventive maintenance and
considers this orientation as priority from many points of vi-
ew. Particular importance is given to the earliest revealing of
a neoplastic primordium before steady community of cells
and tumoral angiogenesis form. The etiology of cancer is
much wider than separately taken causal agent and hinges on
the most complicated interrelation and hierarchy of many
external and internal influences. Our researches with use of
fluorescing antibodies to AFP, CEA and Са-19-9 have sho-
wn that they are intensively precipitated on the cultivated ma-
lignant cells’ surface. Envelopment of cancer cells by onco-
fetal antigens and fibrin (antifibrinogenic luminescing whey, 
raster electronic microscopy) creates exclusive conditions
for their adaptation and growth. It is the basic mechanism of
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tolerance and immunological escape, similarly to pre gnancy
when «the maximal immunological most-favored status» to
developing fetus (semiallogenic transplant) is provided. The
necessity of the specific compensation of the weakened
antineoplastic resistibility of people from high oncological
risk groups is substantiated. With that end in view we have
created Embryonic anti-tumor modulator (EATM), which
comprises a wide pool of fetal proteins and proteoglycans of
normal embryonic origin. EATM possesses also an antimu-
tagen, interferonogenic, immune-response modulating and
antiviral influence in experiment. The EATM injected once a 
year in extremely low doses brings on a specific sensitization 
of cells of the mononuclear-macrophage system aimed at
devitalization of first cancer cells, permanently originating
in adults and older persons. Vaccinal prevention of adults
and older persons, who are amenable to becoming of malig-
nant tumour, is argued. 
Electrophysiological study of the spinal cord
motoneurons on the model of Parkinson’s disease
induced by rotenone
A. A. Nalbandyan, M. V. Poghosyan, V. A. Chavushyan,
J. S. Sarkissian
L. A. Orbeli Institute of Physiology, NAS of Republic of Armenia, Yerevan
johnsarkissyan@gmail.com
Parkinson disease (PD) is a progressive, age-related neu-
rodegenerative disorder, second in frequency only to Alz-
heimer’s disease. It affects tens of millions of people
worldwide. The disease is characterized by poverty of vo-
luntary movements (akinesia), slowness and impaired
scaling of voluntary movement (bradykinesia), muscle
rigidity and tremor of the limbs at rest. The core, but not ex-
clusive pathology is the degeneration of the dopaminergic
neurons in the substantia pars compacta (SNc) of the
midbrain that project to the striatum (Hammond et al.,
2007). Recent studies focused on the contribution of non-
genetic and environmental factors to the development of
sporadic form of Parkinson disease. The action of pesti-
cides is of interest among the pointed factors. Particularly
the chronic administration of herbicide rotenone is leads to
PD-like pathology in rats (Hanan et al., 2004).  The study of 
mechanisms of motor symptoms developmed on spinal
level provided by form of synaptic potentiation and de-
pression, caused by unbalance of dopamine (DA) and
acetylcholine and prevalence of cholinergic activity (Ca-
labresi et al., 2006). There are arguments presented in
favour of the secondarity of pathophysiology of motor
complications, based on decrease of  DA neurons number
(Linazasoro, 2007). The aim of the project was to in-
vestigate whether parkinsonism have severe effect on the
spinal cord neurons activity. Our main interest was how the
motoneurons reveal in condition of rotenone induced
parkinsonism, as SNc neurons activity has been studied in
the same conditions (Sarkissian et al., 2007). Experiments
were carried out on intact rats (n = 4), bilateral injected by
rotenone into medial forebrain bundle per coordinates of
stereotaxic atlas (Paxinos, Watson, 2005). The mathe-
matical programmed analysis of single spike activity of
spinal cord (SC) motoneurons (MN) under high frequency
stimulation (HFS) SN and sciatic nerve (S) 12 weeks ago
was carried out with special software. The activity was
expressed as tetanic potentiation (TP) and depression (TD)
with subsequent posttetanic potentiation and depression.
TP MN of the SC evoked by HFS of SN in norm reached
3-fold increase as compared with prestimulus level. TD
expressed as 3-fold decrease. TP on stimulation S revealed
in the form of 7-fold increase, and TD in 4-fold decrease. In
conditions of rotenone administration poststimulus activity
on HFS SN and S ranged as TP 1.8-fold increase, TD
2.3-fold decrease and TP – 3.4-fold and TD – 4-fold,
respectively. Thereby, the effects of HFS of S in norm were
more significant as compared with those of SN. As regards
the excitatory effects of SN and S stimulation in pathology,
they appeared almost 2 time decreased. Depressive ma-
nifestation of activity in pathology turned out appro-
ximately about to norm. There was expressed burst ac-
tivation of MN, preserved after HFS. We can suppose the
preservation of inhibition as a protection and formation of
burst activity on base of release of locomotor centers of
spinal cord resulted from inhibition of suprasegmental
control.
Treatment with a BH3 mimetic overcomes the
resistance of latency III EBV (+) cells to p53-
mediated apoptosis
A. Pujals, B. Renouf, A. Robert, S. Chelouah, E. Hollville,
J. Wiels 
UMR 8126 CNRS, Univ. Paris-Sud, Institute Gustave Roussy,
Villejuif, France
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Inactivation of the p53 tumor suppressor is often observed in
Burkitt’s lymphoma (BL) cells, due to mutations in the TP53
gene or overexpression of its negative regulator, MDM2.
This inactivation is now considered an essential part of the
oncogenic process. On this other hand, Epstein-Barr virus
(EBV) is strongly associated with BL and is a cofactor in its
development. In previous studies, we showed that nutlin-3,
an antagonist of MDM2, activates the p53 pathway in BL
cell lines harboring wild type p53, regardless of EBV status.
However, nutlin-3 strongly induced apoptosis in EBV (–) or
latency I EBV (+) cells, whereas latency III EBV (+) cells
were much more resistant. We now show that this resistance
to apoptosis is also observed in latency III EBV (+) lym-
phoblastoid cell lines (LCL), a recognized model for the
study of post-transplantation lympho-proliferative disorders
(PTLD). We also show that, in latency III EBV (+) cells,
Bcl-2 is selectively overproduced, interacts with Bax and
thereby prevents Bax activation. The treatment of these cells
with the BH3 mimetic ABT-737 disrupts Bax/Bcl-2 inter-
action and allows Bax activation by nutlin-3. Furthermore,
treatment with these two compounds strongly induces apop-
tosis. Thus, a combination of Mdm2 and Bcl-2 inhibitors
might be a useful anti-cancer strategy for diseases linked to
EBV infection.
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The ITSN1 interactom and its functions
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Aim. Adaptor/scaffold proteins serve as platforms for the as- 
sembly of multiprotein complexes and regulate the effi-
ciency and specificity of signalling cascades. Intersectins
(ITSNs) are an evolutionarily conserved adaptor protein
family engaged in endo- and exocytosis, actin cytoskeleton
rearrangements and signal transduction. Abnormalities of
ITSN1 expression were associated with the endocytic ano-
malies reported in Down syndrome brains and early stages of 
Alzheimer’s disease. Overexpression of ITSN1 was shown
to enhance huntingtin aggregation and neurodegeneration in
Huntington’s disease. Moreover, ITSN2 was proposed to be
a predictive marker for breast cancer. Although significant
progress has been made toward understanding ITSN func-
tions, the role of ITSNs in disease development and re-
gulation of ITSNs function in different cell processes re-
mains unclear. The aim of present study was to uncover no-
vel ITSN binding proteins, to elucidate the ITSN inter-
actom functions and their regulation in a view of ITSN dys-
function under pathological conditions. Methods. Immu-
noprecipitations, pull-down experiments, determination of
subcellular localization by direct and indirect immunofluo-
rescence, mass-spectrometry. Results. Using mass spectro-
metry analysis and in silico prediction we identified 11 novel 
protein partners of ITSN1 and ITSN2, among them adaptor
proteins Ruk/CIN85, Reps1 and SHB as well as ubiquitin
protein ligase Cbl-b and negative regulator of receptor
tyrosine kinases Sprouty 2, implicated in regulation of cel-
lular signal transduction. ITSN1 and its shortest alternatively 
spliced isoform ITSN1-22a form complex with membra-
ne-deforming proteins SGIP1 and amphyphisin, respecti-
vely. An interaction of ITSN1 with WASP-interacting pro-
tein WIP suggests a possible role of ITSN1 in the regulation
of protein complexes during invadopodia formation in can-
cer cells. We also identified a new neuron-specific protein
partner MAP6/STOP involved in microtubule stabilization
and generation of synaptic plasticity. Our results demonst-
rated that ITSN1 could be regulated by ubiquitylation. The
Nedd4-like E3 ubiquitin ligase AIP4 is involved in post-
translational modification of ITSN1 isoforms. Using Xeno-
pus animal model we have demonstrated the role of ITSN2 in 
the coordinated changes of actin cytoskeleton during early
embryonic development. Overexpression of functional do-
mains of ITSN2 in embryos resulted in aberrant phenotypes.
The strongest phenotype was produced by the DH-PH tan-
dem, a nucleotide exchange factor for the small GTPase
Cdc42. Embryos displayed hyperpigmentation and inhi-
bition of gastrulation movements that were incompatible
with survival. Conclusions. These findings expand the role
of ITSNs as a scaffolding molecules bringing together com-
ponents of endocytic and signalling complexes. Identified
ITSN interacting proteins are involved in signal transduc-
tion, actin and tubulin cytoskeleton formation, endocytosis,
cell adhesion and migration. The functional characterization
of novel established links and their contribution to the patho- 
genesis is a challenge for future investigations.
Comparative protective and regenerative effects of
hypothalamic proline-rich peptide – PRP-1, cobra
venom Naja Naja Oxiana, cerebellar and
hypothalamic inhibition on dynamics of vestibular
compensation  following unilateral labyrinthectomy
V. H. Sarkisian, J. S. Sarkissian, A. A. Galoyan1  
L. A. Orbeli Institute of Physiology, NAS of  Republic of Armenia, Yerevan 
1H. Buniatian Institute of Biochemistry, NAS of Republic of Armenia,
Yerevan 
vsargsyan@neuroscience.am
Programming mathematical analysis of Deiters’ lateral ves-
tibular nucleus (LVN) ineurons impulse activity to high fre-
quency stimulation (HFS) of the hypothalamic paraventri-
cular (PVN) and supraoptic (SON) nuclei and cerebellar
anterior lobe (lobules I-V) was carried out. The proline-rich
peptide (PRP-1) and cobra venom Naja Naja Oxiana (NOX)
influence on Deiters’ neurons upon dynamics of vestibular
compensation after unilateral labyrinthectomy (UL) was tes-
ted. Early and late tetanic (TP), – post tetanic potentiation
(PTP) and depression (TD and PTD) of neurons to bilateral
HFS of PVN and SON was studied. The analysis of spike
activity by on-line selection and special program as well as
the construction of complex averaged peri-event time and
frequency histograms were realized. The increasing of in-
hibitory and excitatory reactions of Deiters’ neurons at early
stage of vestibular compensation following PRP-1 and NOX
injection reaching the norm at late stage was revealed. In his- 
tochemical study revealing of the activity of Са2+-dependent
acidic phosphatase (AP) was carried out. In UL animals’ the
delay of central chromatolysis of Deiters’ neurons, leading to 
deep neurodegenerative pattern of cellular shade, up to its
total disappearance was shown. The AP activity after UL and 
PRP-1 injection exerts more favorable influence in com-
parison with expressive venom effects. In intact rats HFS of
the cerebellar lobules I-V showed predominantly depressor
tetanic manifestations of activity (TD), more pronounced at
100 Hz, but with twice smaller prestimulus frequency level
of activity, as compared with that at 50 Hz. On 3d day after
UL at 50 Hz HFS of cerebellar cortex occurred in TD LVN
neurons, similar to that of intact rats, but in a more than twice
expressed background frequency of activity and usually ac-
companied by posttetanic inhibitory and excitatory effects.
Along with this, there was a profound scarcity of TP to HFS
of the cerebellar vermis with a stationary of activity in the
norm and after the UL followed by posttetanic potentiation.
At 9th day after the UL in conjunction with the PRP-1 in-
jection, both on intact and damaged sides depression was not
completely reached the level of the norm, but was relatively
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greater on the injured side. In general at 3d day after the UL
on the injured side TD did not differ from that of 9th day, and
TP was slightly lower than that of the 9th day on the intact
side. In other words, in conditions of UL activity of the LVN
neurons to HFS of cerebellum was characterized by de-
epening of depression and joining to the tetanic effects also
the posttetanic manifestations of activity. The increased de-
pressive effects at 9th day after the UL may not be assumed
without the protective effects of PRP-1. The presence in
LVN neurons almost equally excitatory and depressive ef-
fects, realizing by  HFS of hypothalamic paraventricular and
supraoptic nuclei at 3d  day after the UL, in contrast to the ce-
rebellar effect, indicate their regulatory impact. Moreover,
when HFS of both hypothalamic nuclei TP at LVN level, in
pathology and the norm is actually was the same, in contrast
to depression, which in the pathology was more pronounced
than in the norm, indicating the greater expression of the hy-
pothalamic depression compared with cerebellar effects. The 
inhibitory protection of LVN neurons during UL is suspec-
ted. In conclusion, it is possible that in respect of autono-
mous and motor manifestations of the multiple functioning
of the vestibular complex, the mentioned hypothalamic regu- 
lation predominantly forms inhibitory output of the cerebel-
lar cortex at the level of LVN.
Nitric oxide and GLUT1 transporter: targets for
prevention of diabetes mellitus complications
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Diabetes mellitus (DM) and its complications cause nume-
rous health and social problems throughout the world.
Pathogenic action of nitric oxide (NO) is responsible to a
large extent for development of complications of the disease. 
Abnormal NO production causes blood vessel anomalies in
DM patients, as well as diabetic nephropathy, retinopathy,
myocardiopathy  and hypertension. Thus search for compo-
unds modifying NO production in DM patients appears to be
important for development of pharmacological remedies for
treatment of DM complications. Dihydropiridines (DHP) ap- 
pear to be prospective compounds from this point of view.
DHP are known to be potent regulators of Ca2+ transport,
both Ca2+ blockers and agonists of Ca2+ channels have been
identified between these compounds. Numerous novel DHPs 
were synthesized in the Latvian Institute of Organic Synthe-
sis (IOS), several novel drugs were developed. One of these
compounds, cerebrocrast, manifests pronounced antidiabetic 
activity. The goal of the present work was to study alte-
rations of NO production in streptozotocin model of DM in
rats and ability of several DHPs and to normalize NO syn-
thesis. Mildronate, an inhibitor of fatty acid beta-oxidation
developed in IOS, which also manifests antidiabetic activity
was used as a reference drug. Production of nitric oxide was
monitored by means of ESP spectroscopy of Fe-DETC-NO
complex. Development of streptozotocin diabetes was follo-
wed by increase of NO production in the liver, kidneys, blo-
od and muscles. Cerebrocrast treatment was followed by
normalization of NO production in the liver, kidneys and
blood. Another DHP etaftoron administered in similar dose
was effective in kidneys, blood and muscles. Fenaftoron
decreased NO production in the liver of diabetic animals and
also kidneys, blood and muscles. Mildronate did modify
much NO production in diabetic animals; however it nor-
malized the overexpression of the iNOS gene in kidneys. Elu-
cidation of the DHP action site in the mechanism of the NO
production will be the goal of our future studies. As the stu-
died DHP are Ca2+ channel blockers constitutive NO syntha-
ses seem to be most the likely candidates for targets of these
drugs. Glucose transport via GLUT1 protein could be one of
additional mechanism of the drug anti-diabetic action. To
test this hypothesis we have performed a study of GLUT1
gene and protein expression in the course of the strepto-
zotocin diabetes model development and under treatment
with glibenclamide, metformin and mildronate. Induction of
streptozotocin diabetes provoked increase of both GLUT1
gene and protein expression in kidneys, tretment with gliben-
clamide, metformin and mildronate treatment produced
normalization of the GLUT1 expression levels. This indica-
tes that decrease of GLUT1 in kidneys is a common feature
of anti-diabetic activity of different drugs. This effect pre-
vents development of nephrosclerosis in diabetics. 
PSMC6 gene associations with autoimmune diseases 
in Latvian population
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Introduction. Development of autoimmune diseases is com- 
plex process dependent on genetic predisposition, stress and
environment. Proteasome dysfunction plays an important
role in pathogenesis of autoimmune diseases, thus we found
interesting to find out possible associations of proteasomal
gene polymorphisms with autoimmune diseases. Eight pro-
teasomal genes (PSMB5, PSMB11, PSME1, PSME2, PSMA6, 
PSMC6, PSMA3, PSMC1) are located on human Chromo-
some 14, distributed in  loci14q11, 14q13, 14q23-24, 14q42.
PSMC6 gene is one of representatives of this cluster, it en-
codes proteasome 19S complex ATPase subunit 6, and possi-
bly it is associated with autoimmune disease pathogenesis.
Goal. To analyze possible PSMC6 gene c.86–104A > G and
c.86–46C > T SNP associations with autoimmune diseases in 
Latvian population. Methods. DNA samples were obtained
from three groups of individuals: healthy controls, juvenile
idiopathic arthritis patients and bronchial asthma patients.
Samples were amplified, using primer specific polymerase
chain reaction, amplification products digested with DdeI
restrictase, size of digestion products was evaluated by
means of electrophoresis. Results. Our studies bring eviden-
ce that several polymorphisms of PSMC6 gene are associa-
ted with autoimmune diseases or their specific subtypes.
Analyzing c.86–104A > G SNP we found correlations with
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juvenile idiopathic arthritis and oligoarthritis subtype. In
c.86–46C > T SNP case no similar correlations were found.
Our data demonstrate, that a linkage disequilibrium exists in
Latvian population between c.86–104 A > G and c. 86–46C >
> T SNP, this is not the case in other European populations.
This indicates a possible recombination event. Work with
bronchial asthma patient DNA is on line. Conclusions. Our
results indicate and association between c.86–104 A > G and
autoimmune diseases in the Latvian population. PSMC6 ge-
ne is perspective for further association studies.
Blood lymphocyte lipids in diverse forms of cancer
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The involvement of cell plasma membrane (PM) lipids in the
regulatory mechanisms of various important membrane-bo-
und processes is well documented. These compounds by chan-
ging their composition and structure (microdomain) orga-
nization respond rapidly to different environmental pertur-
bations, especially leading to the pathologies. However, the
role of lipids and enzyme systems of their modification in
cancer is not studied in detail. It is well known that compared 
to normal individuals, patients with several types of cancer
have an increased prevalence of regulatory T cells (Treg),
coexpressing CD4, CD25 and Treg marker FOXP3, in the peri-
pheral blood, tumor microenvironment and tumor draining
lymph nodes. The increase in Treg that suppresses autoimmu-
nity may also inhibit the immune response against cancer, as
evidenced by improved tumor rejection and survival of tu-
mor-bearing mice that have undergone Treg depletion. It was
hypothesized by us earlier that in such intricate system disea- 
ses, as human tumors, alterations in PM lipid homeostasis in
the peripheral blood crude lymphocytes may possibly repre-
sent some information useful for detection and state value of
diverse cancers as well as for the personalized correction of
chemotherapy treatment modes. We investigated early (5 s)
and long-term (60 min) acylation of membrane lipids by
different exogenous [14C]fatty acids (FA) in lymphocytes
isolated from the peripheral blood of patients with diverse
forms of leukemia and solid tumors in comparison with the
healthy people. Changes in the endogenous activities of
some lipid-modifying enzymes in purified PM fraction as
well as the mechanisms of diverse lipid second messengers
(LSM) formation in [14C]arachidonic acid-prelabelled intact
lymphocytes were also investigated at different time points
(5, 10, 30 and 60 s) following T cell costimulation by an-
ti-CD3/CD28 antibodies. The data obtained provide evi-
dence for reproducible defects in lymphocyte lipids FA
content modification and different LSMs generation/utili-
zation processes in studied forms of cancer. Importantly,
identical alterations were revealed in all forms of disease
mainly at the early (5 s) membrane-bound stage of cell sti-
mulation. We also found that Ca2+-dependent activities of
phospholipases A1, A2 and C detected in purified PM frac-
tion of lymphocytes were significantly or completely inhi-
bited in all cancer types. Notably, abnormally high lyso-
phosphatidylcholine acylhydrolase activity, which was dis-
tinctly individual for each patient, was observed in lympho-
cytes obtained from cancer patients, but not in normal
controls. We conclude that some of the observed alterations
are common characteristics of all types of cancer studied,
and can lead to the discovery of novel drug targets and new
personalized treatment modes of disease (Tadevosyan Y. V.
et al., 2008; Patent AM2256, G01N 33/534; Tadevosyan Y.
V. et al., 2009, Patent AM2311, G01N 33/53). 
Novel functions for ubiquitylation in nuclear
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Concomitantly to their transcription, nascent transcripts un-
dergo a series of orchestrated modifications resulting in the
formation of stable and export-competent mRNPs. Impor-
tantly, mRNPs are constantly remodeled during their bioge-
nesis with most processing factors being removed prior to
transport to the cytoplasm. Several years ago, we proposed
that posttranslational modifications by ubiquitin and recogni-
tion by ubiquitin binding domains could play a major role in
the dynamics of the supramolecular scaffolds involved in
mRNA biogenesis. We originally focused on the UBA of the
yeast mRNA nuclear export receptor Mex67. This domain is
not only required for mRNA nuclear export, but also contri-
butes to the coordination of transcription and mRNA export
via its ability to interact with ubiquitylated target proteins.
Our recent data indicate that histone ubiquitylation also
influences the appropriate assembly of mRNP. Monoubiqui-
tylation of histone H2B indeed controls integrity and sta-
bility of the cleavage and polyadenylation factor, which it-
self monitors recruitment of nuclear export factors sugges-
ting a direct relationship between histone modifications and
posttranscriptional events. Finally, ubiquitylation processes
also regulate dissociation of some nuclear factors prior trans- 
port to the cytoplasm. Nuclear export of mRNP occur thro-
ugh NPCs, large channels anchored in the nuclear envelope.
We determined the ubiquitylation status of all the nucleopo-
rins in yeast and found that ubiquitylation of the NPC might
be associated to broad functions of the NPC. In particular,
we identified an unexpected role for ubiquitylation of Nup
159, a nucleoporin located at the cytoplasmic face of the
NPC, in cell cycle progression. 
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SAYP and Brahma are important for «repressive»
and «transient» Pol II promoter-proximal pausing
N. Vorobyeva, J. Nikolenko, E. Nabirochkina, A. Krasnov,
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Drosophila SAYP the homologue of human PHF10/BAF45a 
is metazoan coactivator that is associated with Brahma
complex. SAYP is essential for the recruitment of TFIID and
Brahma on promoters of actively transcribed genes. Here we
studied the role of SAYP in DHR3 activator driven trans-
cription of ftz-f1 gene encoding NR, the member of ecdysone 
cascade. The repressed state of the ftz-f1 is formed by trans-
cription stalling and is characterized by pre-recruited Pol II
complex on promoter and Pol II promoter-proximal pausing
around 1.5 kb downstream the start of transcription. SAYP
and Brahma form «nucleosome barrier», the region of high
nucleosome density ahead of paused Pol II. RNAi knock-
down of SAYP leads to Brahma removel, elimination of nuc- 
leosome barrier and to the synthesis of the full-length trans-
cript. During active transcription Pol II is also paused at 1.5
kb downstream promoter. In line with general view this
promoter-proximal pausing correlates with Pol II CTD Ser2
phosphorylation. Knockdown of SAYP represses the Ser2
CTD phosphorylation, interferes with transcription elon-
gation and increases the time interval in which transcription
maximum is reached. Thus SAYP as a part of Brahma
complex participates both in repressive and transient Pol II
pausing. 
